Β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells

V. Morello, S. Cabodi, S. Sigismund, M. P. Camacho-Leal, D. Repetto, M. Volante, M. Papotti, E. Turco, P. Defilippi

Research output: Contribution to journalArticle

Abstract

Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. Our previous work demonstrated that in epithelial cells Β1 integrin is required for propagating EGFR signaling from the plasma membrane to the nucleus. In this study, we silenced Β1 integrin in human NSCLC A549 cells. The Β1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Inhibitory effects on tumor growth and on the EGFR pathway were also observed in in vivo experiments. Moreover, Β1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that Β1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that Β1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that Β1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.

Original languageEnglish
Pages (from-to)4087-4096
Number of pages10
JournalOncogene
Volume30
Issue number39
DOIs
Publication statusPublished - Sep 29 2011

Fingerprint

Epidermal Growth Factor Receptor
Integrins
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Cell Membrane
Neoplasms
Recycling
Epidermal Growth Factor
Cisplatin
Cause of Death
Epithelial Cells
Therapeutics
Growth

Keywords

  • β1 integrin
  • EGFR
  • lung cancer

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Morello, V., Cabodi, S., Sigismund, S., Camacho-Leal, M. P., Repetto, D., Volante, M., ... Defilippi, P. (2011). Β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene, 30(39), 4087-4096. https://doi.org/10.1038/onc.2011.107

Β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. / Morello, V.; Cabodi, S.; Sigismund, S.; Camacho-Leal, M. P.; Repetto, D.; Volante, M.; Papotti, M.; Turco, E.; Defilippi, P.

In: Oncogene, Vol. 30, No. 39, 29.09.2011, p. 4087-4096.

Research output: Contribution to journalArticle

Morello, V, Cabodi, S, Sigismund, S, Camacho-Leal, MP, Repetto, D, Volante, M, Papotti, M, Turco, E & Defilippi, P 2011, 'Β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells', Oncogene, vol. 30, no. 39, pp. 4087-4096. https://doi.org/10.1038/onc.2011.107
Morello V, Cabodi S, Sigismund S, Camacho-Leal MP, Repetto D, Volante M et al. Β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene. 2011 Sep 29;30(39):4087-4096. https://doi.org/10.1038/onc.2011.107
Morello, V. ; Cabodi, S. ; Sigismund, S. ; Camacho-Leal, M. P. ; Repetto, D. ; Volante, M. ; Papotti, M. ; Turco, E. ; Defilippi, P. / Β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. In: Oncogene. 2011 ; Vol. 30, No. 39. pp. 4087-4096.
@article{efecc5e1f66e478ba0a7950cc72a55bc,
title = "Β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells",
abstract = "Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. Our previous work demonstrated that in epithelial cells Β1 integrin is required for propagating EGFR signaling from the plasma membrane to the nucleus. In this study, we silenced Β1 integrin in human NSCLC A549 cells. The Β1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Inhibitory effects on tumor growth and on the EGFR pathway were also observed in in vivo experiments. Moreover, Β1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that Β1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that Β1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that Β1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.",
keywords = "β1 integrin, EGFR, lung cancer",
author = "V. Morello and S. Cabodi and S. Sigismund and Camacho-Leal, {M. P.} and D. Repetto and M. Volante and M. Papotti and E. Turco and P. Defilippi",
year = "2011",
month = "9",
day = "29",
doi = "10.1038/onc.2011.107",
language = "English",
volume = "30",
pages = "4087--4096",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "39",

}

TY - JOUR

T1 - Β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells

AU - Morello, V.

AU - Cabodi, S.

AU - Sigismund, S.

AU - Camacho-Leal, M. P.

AU - Repetto, D.

AU - Volante, M.

AU - Papotti, M.

AU - Turco, E.

AU - Defilippi, P.

PY - 2011/9/29

Y1 - 2011/9/29

N2 - Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. Our previous work demonstrated that in epithelial cells Β1 integrin is required for propagating EGFR signaling from the plasma membrane to the nucleus. In this study, we silenced Β1 integrin in human NSCLC A549 cells. The Β1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Inhibitory effects on tumor growth and on the EGFR pathway were also observed in in vivo experiments. Moreover, Β1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that Β1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that Β1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that Β1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.

AB - Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. Our previous work demonstrated that in epithelial cells Β1 integrin is required for propagating EGFR signaling from the plasma membrane to the nucleus. In this study, we silenced Β1 integrin in human NSCLC A549 cells. The Β1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Inhibitory effects on tumor growth and on the EGFR pathway were also observed in in vivo experiments. Moreover, Β1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that Β1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that Β1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that Β1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.

KW - β1 integrin

KW - EGFR

KW - lung cancer

UR - http://www.scopus.com/inward/record.url?scp=80053320001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053320001&partnerID=8YFLogxK

U2 - 10.1038/onc.2011.107

DO - 10.1038/onc.2011.107

M3 - Article

C2 - 21478906

AN - SCOPUS:80053320001

VL - 30

SP - 4087

EP - 4096

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 39

ER -